You have 9 free searches left this month | for more free features.

Intratumoral gemcitabine levels

Showing 26 - 50 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative Trial in Houston (Doxorubicin,

Recruiting
  • Metastatic Kidney Medullary Carcinoma
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 20, 2023

Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck Trial in United States (Drug: SL-172154)

Terminated
  • Cutaneous Squamous Cell Carcinoma
  • Squamous Cell Carcinoma of Head and Neck
  • Drug: SL-172154
  • Los Angeles, California
  • +5 more
May 18, 2022

Metastatic Pancreatic Cancer Trial in Spain (OMO-103, Nab-Paclitaxel, Gemcitabine)

Recruiting
  • Metastatic Pancreatic Cancer
  • L´Hospitalet de Llobregat, Barcelona, Spain
  • +3 more
Sep 22, 2023

Prostatic Tumors Trial in San Francisco (Pembrolizumab, SD-101, Leuprolide acetate)

Active, not recruiting
  • Prostatic Neoplasms
  • San Francisco, California
    University of California San Francisco
Sep 20, 2022

Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB Trial in Shanghai (sintilimab,

Not yet recruiting
  • Pancreatic Cancer, Stage IB
  • +3 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital
Jan 4, 2023

Recurrent NSCLC, Stage IV NSCLC Trial in Detroit (docetaxel, pemetrexed disodium, gemcitabine HCl)

Terminated
  • Recurrent Non-small Cell Lung Cancer
  • Stage IV Non-small Cell Lung Cancer
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Sep 3, 2020

Pancreatic Adenocarcinoma, Metastatic Trial in Spain, United States (Nab-paclitaxel, Gemcitabine, VCN-01)

Not yet recruiting
  • Pancreatic Adenocarcinoma
  • Metastatic
  • New York, New York
  • +7 more
Jan 3, 2023

Soft Tissue Sarcoma Trial in Winston-Salem (drug, radiation, procedure, other)

Recruiting
  • Soft Tissue Sarcoma
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
Jan 26, 2023

Ovarian Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma Trial in Canada, Singapore, United States

Active, not recruiting
  • Ovarian Brenner Tumor
  • +11 more
  • Duarte, California
  • +15 more
Aug 11, 2022

Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic Trial in Scottsdale (Botensilimab, Balstilimab, Chloroquine

Not yet recruiting
  • Pancreatic Cancer Metastatic
  • Pancreatic Adenocarcinoma Metastatic
  • Scottsdale, Arizona
    Clinical Trials Nurse Navigator
Oct 3, 2023

Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8 Trial

Recruiting
  • Borderline Resectable Pancreatic Adenocarcinoma
  • +5 more
  • Durvalumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Diffuse Intrinsic Pontine Glioma Trial in Aurora (Gemcitabine)

Recruiting
  • Diffuse Intrinsic Pontine Glioma
  • Aurora, Colorado
    Children's Hospital Colorado
Jan 31, 2022

Pancreatic Cancer Trial in Meldola, Ravenna (Losartan, Gemcitabine, Nab paclitaxel)

Not yet recruiting
  • Pancreatic Cancer
  • Meldola, Forlì, Italy
  • +1 more
May 12, 2023

Pancreatic Cancer, Metastatic Adenocarcinoma Trial in Winston-Salem (Nab paclitaxel, Gemcitabine, TheraBionic)

Not yet recruiting
  • Pancreatic Cancer
  • Metastatic Adenocarcinoma
  • Nab paclitaxel
  • +2 more
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
Mar 8, 2023

Gastric Adenocarcinoma Trial in Pessac (Gastrectomy)

Recruiting
  • Gastric Adenocarcinoma
  • Gastrectomy
  • Pessac, France
    Hôpital du Haut Lévêque
Mar 23, 2023

Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma Trial in Indianapolis (Lonsurf, Gemcitabine, Nab-Paclitaxel)

Active, not recruiting
  • Pancreatic Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Indianapolis, Indiana
    Indiana University Melvin & Bren Simon Cancer Center
Nov 29, 2022

Non-Squamous Non-Small Cell Lung Carcinoma, Stage I NSCLC, Stage IA Non-Small Cell Lung Carcinoma Trial in Abington,

Active, not recruiting
  • Non-Squamous Non-Small Cell Lung Carcinoma
  • +7 more
  • Nivolumab
  • +3 more
  • Abington, Pennsylvania
  • +1 more
Sep 14, 2022

Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma Trial in

Active, not recruiting
  • Locally Advanced Pancreatic Adenocarcinoma
  • +4 more
  • Biopsy
  • +4 more
  • Chicago, Illinois
  • +11 more
Jun 28, 2022

Leiomyosarcoma, Adult Trial in France (Association of berzosertib with gemcitabine, Gemcitabine)

Recruiting
  • Leiomyosarcoma, Adult
  • Bordeaux, France
  • +5 more
Jul 27, 2022

Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +5 more
  • Duarte, California
  • +3 more
Nov 17, 2022

Testicular Cancer Trial in Houston, Seattle (Gemcitabine, Docetaxel, Melphalan)

Active, not recruiting
  • Testicular Cancer
  • Houston, Texas
  • +1 more
Dec 5, 2022

Tumors, High Grade Glioma, Glioblastoma Multiforme Trial in Birmingham (Biological G207)

Not yet recruiting
  • Neoplasms
  • +7 more
  • Biological G207
  • Birmingham, Alabama
    Children's of Alabama
Jun 1, 2022

Melanoma Stage IIIB/C Trial in Spain, Switzerland, United States (Daromun, Surgery, Adjuvant therapy)

Recruiting
  • Melanoma Stage IIIB/C
  • La Jolla, California
  • +30 more
Dec 22, 2022

Malignant Tumor of Bone and Articular Cartilage, Malignant Tumors of Female Genital Organs, Malignant Tumors of Independent

Recruiting
  • Malignant Neoplasm of Bone and Articular Cartilage
  • +9 more
  • Houston, Texas
    The University of Texas MD Anderson Cancer Center
Oct 26, 2022

Lymphoma, Solid Tumor Trial in Buffalo (Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study)

Terminated
  • Lymphoma
  • Solid Neoplasm
  • Gemcitabine Hydrochloride
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 20, 2022